243 related articles for article (PubMed ID: 17672443)
41. Differential effects of manoalide on secreted and intracellular phospholipases.
Bennett CF; Mong S; Clarke MA; Kruse LI; Crooke ST
Biochem Pharmacol; 1987 Mar; 36(5):733-40. PubMed ID: 3103628
[TBL] [Abstract][Full Text] [Related]
42. 4-Alkoxybenzamidines as new potent phospholipase A2 inhibitors.
Aitdafoun M; Mounier C; Heymans F; Binisti C; Bon C; Godfroid JJ
Biochem Pharmacol; 1996 Mar; 51(6):737-42. PubMed ID: 8602868
[TBL] [Abstract][Full Text] [Related]
43. Synthesis and evaluation of trimethoxyphenyl isoxazolidines as inhibitors of secretory phospholipase A2 with anti-inflammatory activity.
Sadashiva MP; Nataraju A; Mallesha H; Rajesh R; Vishwanath BS; Rangappa KS
Int J Mol Med; 2005 Nov; 16(5):895-904. PubMed ID: 16211261
[TBL] [Abstract][Full Text] [Related]
44. Studies on the anti-phospholipase A2 and anti-inflammatory activities of a uteroglobin fragment and related peptides.
Marastoni M; Scaranari V; Romualdi P; Donatini A; Ferri S; Tomatis R
Arzneimittelforschung; 1993 Sep; 43(9):997-1000. PubMed ID: 8240467
[TBL] [Abstract][Full Text] [Related]
45. Multiple phospholipase A2 enzymes participate in the inflammatory process in osteoarthritic cartilage.
Leistad L; Feuerherm AJ; Faxvaag A; Johansen B
Scand J Rheumatol; 2011; 40(4):308-16. PubMed ID: 21417548
[TBL] [Abstract][Full Text] [Related]
46. Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases.
Yarla NS; Bishayee A; Vadlakonda L; Chintala R; Duddukuri GR; Reddanna P; Dowluru KS
Curr Drug Targets; 2016; 17(16):1940-1962. PubMed ID: 26212262
[TBL] [Abstract][Full Text] [Related]
47. Differential inhibition of human secretory and cytosolic phospholipase A2.
Märki F; Breitenstein W; Beriger E; Bernasconi R; Caravatti G; Francis JE; Paioni R; Wehrli HU; Wiederkehr R
Agents Actions; 1993 Mar; 38(3-4):202-11. PubMed ID: 8213347
[TBL] [Abstract][Full Text] [Related]
48. Continuous, vesicle-based fluorimetric assays of 14- and 85-kDa phospholipases A2.
Bayburt T; Yu BZ; Street I; Ghomashchi F; Laliberté F; Perrier H; Wang Z; Homan R; Jain MK; Gelb MH
Anal Biochem; 1995 Nov; 232(1):7-23. PubMed ID: 8600835
[TBL] [Abstract][Full Text] [Related]
49. An investigation of calcium-independent phospholipase A2 (iPLA2) and cytosolic phospholipase A2 (cPLA2) in schizophrenia.
Xu C; Yang X; Sun L; Yang T; Cai C; Wang P; Jiang J; Qing Y; Hu X; Wang D; Wang P; Cui G; Zhang J; Li Y; Ji F; Liu C; Wan C
Psychiatry Res; 2019 Mar; 273():782-787. PubMed ID: 31207866
[TBL] [Abstract][Full Text] [Related]
50. Labour is associated with increased expression of type-IIA secretory phospholipase A2 but not type-IV cytosolic phospholipase A2 in human myometrium.
Slater DM; Astle S; Bennett PR; Thornton S
Mol Hum Reprod; 2004 Nov; 10(11):799-805. PubMed ID: 15361552
[TBL] [Abstract][Full Text] [Related]
51. Location of inhibitors bound to group IVA phospholipase A2 determined by molecular dynamics and deuterium exchange mass spectrometry.
Burke JE; Babakhani A; Gorfe AA; Kokotos G; Li S; Woods VL; McCammon JA; Dennis EA
J Am Chem Soc; 2009 Jun; 131(23):8083-91. PubMed ID: 19459633
[TBL] [Abstract][Full Text] [Related]
52. Development of a potent 2-oxoamide inhibitor of secreted phospholipase A2 guided by molecular docking calculations and molecular dynamics simulations.
Vasilakaki S; Barbayianni E; Leonis G; Papadopoulos MG; Mavromoustakos T; Gelb MH; Kokotos G
Bioorg Med Chem; 2016 Apr; 24(8):1683-95. PubMed ID: 26970660
[TBL] [Abstract][Full Text] [Related]
53. Synthesis of lipidic amino acid and dipeptide inhibitors of human platelet phospholipase A2.
Kokotos G; Constantinou-Kokotou V; Noula C; Nicolaou A; Gibbons WA
Int J Pept Protein Res; 1996 Aug; 48(2):160-6. PubMed ID: 8872534
[TBL] [Abstract][Full Text] [Related]
54. Inhibitors of secretory phospholipase A2 group IIA.
Reid RC
Curr Med Chem; 2005; 12(25):3011-26. PubMed ID: 16378502
[TBL] [Abstract][Full Text] [Related]
55. Modulation of acute and chronic inflammatory processes by cacospongionolide B, a novel inhibitor of human synovial phospholipase A2.
García Pastor P; De Rosa S; De Giulio A; Payá M; Alcaraz MJ
Br J Pharmacol; 1999 Jan; 126(1):301-11. PubMed ID: 10051149
[TBL] [Abstract][Full Text] [Related]
56. Role of cytoplasmic and secretory phospholipase A2 in intestinal epithelial cell prostaglandin E2 formation.
Grossman EM; Longo WE; Mazuski JE; Panesar N; Kaminski DL
Int J Surg Investig; 2000; 1(6):467-76. PubMed ID: 11729854
[TBL] [Abstract][Full Text] [Related]
57. Chemically modified non-antimicrobial tetracyclines inhibit activity of phospholipases A2.
Pruzanski W; Stefanski E; Vadas P; McNamara TF; Ramamurthy N; Golub LM
J Rheumatol; 1998 Sep; 25(9):1807-12. PubMed ID: 9733464
[TBL] [Abstract][Full Text] [Related]
58. Cytosolic phospholipase A2 enzymes are not required by mouse bone marrow-derived macrophages for the control of Mycobacterium tuberculosis in vitro.
Vandal OH; Gelb MH; Ehrt S; Nathan CF
Infect Immun; 2006 Mar; 74(3):1751-6. PubMed ID: 16495548
[TBL] [Abstract][Full Text] [Related]
59. Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2.
Kokotos G; Hsu YH; Burke JE; Baskakis C; Kokotos CG; Magrioti V; Dennis EA
J Med Chem; 2010 May; 53(9):3602-10. PubMed ID: 20369880
[TBL] [Abstract][Full Text] [Related]
60. Systemic and intrathecal effects of a novel series of phospholipase A2 inhibitors on hyperalgesia and spinal prostaglandin E2 release.
Yaksh TL; Kokotos G; Svensson CI; Stephens D; Kokotos CG; Fitzsimmons B; Hadjipavlou-Litina D; Hua XY; Dennis EA
J Pharmacol Exp Ther; 2006 Jan; 316(1):466-75. PubMed ID: 16203828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
